Hypermethylated Genes of MicroRNA in Ovarian Carcinoma: Metastasis Prediction Marker Systems
- 作者: Filippova E.1, Loginov V.1,2, Burdennyi A.1, Braga E.1,2, Pronina I.1, Kazubskaya T.3, Kushlinskii D.3, Utkin D.3, Fridman M.4, Khodyrev D.5, Kushlinskii N.3
-
隶属关系:
- Research Institute of General Pathology and Pathophysiology
- Research Center for Medical Genetics
- N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
- N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences
- Federal Scientific and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of the Russia
- 期: 卷 167, 编号 1 (2019)
- 页面: 79-83
- 栏目: Oncology
- URL: https://journals.rcsi.science/0007-4888/article/view/241469
- DOI: https://doi.org/10.1007/s10517-019-04465-5
- ID: 241469
如何引用文章
详细
We identified a group of miRNA genes whose methylation is associated with ovarian cancer metastasis. Based on these data, new markers and the systems of markers predicting tumor dissemination were selected. Using methylation-specific PCR and a representative set of 54 ovarian cancer samples, we identified 10 microRNA genes (MIR-124a-2, MIR-127, MIR-125b-1, MIR-129-2, MIR-137, MIR-193a, MIR-203a, MIR-34b/c, MIR-130b, and MIR-1258) whose methylation is associated with tumor metastasis. The greatest association was established for 4 genes: MIR-137, MIR-193a, MIR-34b/c, and MIR-130b (p<0.01). ROC analysis revealed 3 most optimal marker systems including 4-5 miRNA genes and characterized by high sensitivity (82-94%) and specificity (76-86%) at AUC=0.89-0.92. Methylation of any three genes from these systems is sufficient to predict metastasis with the specified accuracy. Detection of the group of hypermethylated miRNA genes with predictive value for ovarian cancer metastasis is of great importance for personalized treatment of the patients.
作者简介
E. Filippova
Research Institute of General Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow
V. Loginov
Research Institute of General Pathology and Pathophysiology; Research Center for Medical Genetics
Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow; Moscow
A. Burdennyi
Research Institute of General Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow
E. Braga
Research Institute of General Pathology and Pathophysiology; Research Center for Medical Genetics
编辑信件的主要联系方式.
Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow; Moscow
I. Pronina
Research Institute of General Pathology and Pathophysiology
Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow
T. Kazubskaya
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow
D. Kushlinskii
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow
D. Utkin
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow
M. Fridman
N. I. Vavilov Institute of General Genetics, Russian Academy of Sciences
Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow
D. Khodyrev
Federal Scientific and Clinical Center of Specialized Medical Care and Medical Technologies, Federal Medical-Biological Agency of the Russia
Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow
N. Kushlinskii
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of the Russian Federation
Email: eleonora10_45@mail.ru
俄罗斯联邦, Moscow